Identification of aberrant circulating mi<scp>RNA</scp>s in Parkinson's disease plasma samples

Chen, Lei; Yang, Junxiu; Lu, Jianrong; Cao, Shanshan; Zhao, Qian; Yu, Zuoren

doi:10.1002/brb3.941

Cited by 83 publications

(63 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Abnormal miRNA expression has been linked to many human diseases, and miRNAs have been identified as diagnostic and prognostic biomarkers for several disorders, including PD 32,33,34,35,36 . However, no PD-specific miRNAs have been identified in the gut for the pre-clinical diagnosis of PD so far 37,38,39 . To address this, we studied functional and molecular changes in the ENS of A30P mice before onset of PD symptoms to identify gut-related biomarkers for early stages of PD.…”

Section: Introductionmentioning

confidence: 99%

Functional and molecular early enteric biomarkers for Parkinson’s disease in mice and men

Gries

Christmann

Schulte

et al. 2020

Preprint

View full text Add to dashboard Cite

Parkinson's disease (PD) usually has a late clinical onset. The lack of early biomarkers for the disease represents a major challenge for developing timely treatment interventions. Here, we use an -synuclein-overexpressing transgenic (Th-1-SNCA-A30P) mouse model of PD to identify appropriate candidate markers in the gut for early stages of PD before hallmark symptoms begin to manifest. A30P mice did not show alterations in gait parameters at 2 months of age, and these mice were therefore defined as pre-symptomatic A30P mice (psA30P). We discovered early functional motility changes in the gut and early molecular dysregulations in the myenteric plexus of psA30P mice by comparative protein and miRNA profiling and cell culture experiments. We found that the proteins neurofilament light chain, vesicle-associated membrane protein 2 and calbindin 2, together with the miRNAs that regulate them, are potential biomarkers of early PD that may facilitate timely treatment and/or prevention of PD in men.

show abstract

Section: Introductionmentioning

confidence: 99%

Functional and molecular early enteric biomarkers for Parkinson’s disease in mice and men

Gries

Christmann

Schulte

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Although research into PD has been performed for nearly a century, there is still a large amount of work to be done exploring the pathogenesis of the disease. Accordingly, it is imperative to identify useful biomarkers for early diagnosis of PD, especially prior to the onset of motor symptoms [4]. Up to now, the current therapeutics for PD only alleviates the symptoms, and when the full-blown syndrome occurs, there is no disease-modifying way available to treat the disease.…”

mentioning

confidence: 99%

“…Chen et al [4] provided a set of novel miRNA candidates, including up-regulated miR-27a and downregulated let-7a, miR-142-3p, let-7f and miR-222, for detecting PD. Chen et al [4] provided a set of novel miRNA candidates, including up-regulated miR-27a and downregulated let-7a, miR-142-3p, let-7f and miR-222, for detecting PD.…”

mentioning

confidence: 99%

Identification of potential diagnostic biomarkers for Parkinson's disease

Feng-hua

Sun

et al. 2019

FEBS Open Bio

View full text Add to dashboard Cite

The identification of biomarkers for early diagnosis of Parkinson's disease (PD) prior to the onset of symptoms may improve the effectiveness of therapy. To identify potential biomarkers, we downloaded microarray datasets of PD from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) between PD and normal control (NC) groups were obtained, and the feature selection procedure and classification model were used to identify optimal diagnostic gene biomarkers for PD. A total of 1229 genes (640 up‐regulated and 589 down‐regulated) were obtained for PD, and nine DEGs (PTGDS, GPX3, SLC25A20, CACNA1D, LRRN3, POLR1D, ARHGAP26, TNFSF14 and VPS11) were selected as optimal PD biomarkers with great diagnostic value. These nine DEGs were significantly enriched in regulation of circadian sleep/wake cycle, sleep and gonadotropin‐releasing hormone signaling pathway. Finally, we examined the expression of GPX3, SLC25A20, LRRN3 and POLR1D in blood samples of patients with PD by qRT‐PCR. GPX3, LRRN3 and POLR1D exhibited the same expression pattern as in our analysis. In conclusion, this study identified nine DEGs that may serve as potential biomarkers of PD.

show abstract

“…This finding suggests that cf-microRNAs might discriminate Parkinson's disease multisystem atrophy patients ( 62 ). Recently, Chen et al ( 63 ) suggested that plasma miR-27a might be a potential biomarker of therapeutic targets in Parkinson's disease.…”

Section: Cnas In the Plasma And Serum In Neurological Disordersmentioning

confidence: 99%

Circulating nucleic acids in the plasma and serum as potential biomarkers in neurological disorders

Bruno

Donatti

Martin

et al. 2020

Braz J Med Biol Res

View full text Add to dashboard Cite

Neurological diseases are responsible for approximately 6.8 million deaths every year. They affect up to 1 billion people worldwide and cause significant disability and reduced quality of life. In most neurological disorders, the diagnosis can be challenging; it frequently requires long-term investigation. Thus, the discovery of better diagnostic methods to help in the accurate and fast diagnosis of neurological disorders is crucial. Circulating nucleic acids (CNAs) are defined as any type of DNA or RNA that is present in body biofluids. They can be found within extracellular vesicles or as cell-free DNA and RNA. Currently, CNAs are being explored as potential biomarkers for diseases because they can be obtained using non-invasive methods and may reflect unique characteristics of the biological processes involved in several diseases. CNAs can be especially useful as biomarkers for conditions that involve organs or structures that are difficult to assess, such as the central nervous system. This review presents a critical assessment of the most current literature about the use of plasma and serum CNAs as biomarkers for several aspects of neurological disorders: defining a diagnosis, establishing a prognosis, and monitoring the disease progression and response to therapy. We explored the biological origin, types, and general mechanisms involved in the generation of CNAs in physiological and pathological processes, with specific attention to neurological disorders. In addition, we present some of the future applications of CNAs as non-invasive biomarkers for these diseases.

show abstract

Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples

Cited by 83 publications

References 48 publications

Functional and molecular early enteric biomarkers for Parkinson’s disease in mice and men

Functional and molecular early enteric biomarkers for Parkinson’s disease in mice and men

Identification of potential diagnostic biomarkers for Parkinson's disease

Circulating nucleic acids in the plasma and serum as potential biomarkers in neurological disorders

Contact Info

Product

Resources

About